Health CarePharmaceuticals and Biotechnology
  • Price (EUR)70.50
  • Today's Change-1.30 / -1.81%
  • Shares traded5.35k
  • 1 Year change-10.19%
  • Beta0.7645
Data delayed at least 15 minutes, as of Jun 05 2023 16:39 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Formycon AG is a Germany-based company engaged in providing biosimilar drugs and formulations. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The Company focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.

  • Revenue in EUR (TTM)42.50m
  • Net income in EUR35.99m
  • Incorporated2012
  • Employees205.00
  • Location
    Formycon AGFraunhoferstrasse 15MARTINSRIED 82152GermanyDEU
  • Phone+49 89 864667100
  • Fax+49 89 864667110
  • Websitehttps://www.formycon.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Northern Data AG16.38m-84.26m464.40m162.00--1.62--28.36-7.25-7.251.4112.06------101,094.80--20.18--33.1637.2050.93-514.4885.770.301-0.52520.25190.001,059.28485.60440.81------
MorphoSys AG299.12m-72.84m836.97m623.00--8.61--2.80-2.14-2.148.762.840.12762.204.37475,546.90-3.11-10.92-3.48-12.3279.3788.74-24.35-77.843.46-2.500.7434--54.9333.0370.64--2.98--
Eckert & Zieglr Strahln und Mdzntchnk AG230.30m27.47m858.73m1.01k30.733.8921.853.731.321.3211.0710.420.59013.115.09235,966.207.138.608.5710.3746.9048.1512.0913.532.1524.630.194436.0723.189.90-15.2020.3449.5620.11
Formycon AG42.50m35.99m1.15bn205.0020.493.0530.4227.103.503.503.0823.570.092425.083.66207,302.407.823.038.383.2928.4131.6184.6910.910.5908-554.000.07410.0016.077.86370.82--120.72--
Biotest AG517.40m-47.99m1.46bn2.23k--2.39--2.83-2.43-2.4326.1517.750.44991.353.68232,226.20-4.10-2.63-4.58-2.9823.8325.66-9.10-6.162.08-1.050.6496--0.0976.4250.01---22.75--
Dermapharm Holding SE1.11bn146.27m2.57bn2.56k17.534.4310.372.312.732.7320.7210.780.61291.3211.30433,965.307.9710.969.1412.6465.3360.1913.0014.391.236.880.661640.528.6817.01-35.9545.47-12.19--
Evotec SE751.45m-175.66m3.85bn4.95k--3.23--5.12-0.9942-0.99424.256.720.334520.764.30151,746.40-7.822.35-9.172.8323.1625.86-23.386.223.090.11590.29910.0021.5923.29-181.51--59.47--
Data as of Jun 05 2023. Currency figures normalised to Formycon AG's reporting currency: Euro EUR

Institutional shareholders

9.12%Per cent of shares held by top holders
HolderShares% Held
Active Ownership Corp SARLas of 17 Mar 20231.07m6.70%
MPPM Manfred Piontke Portfolio Management e.K.as of 30 Sep 202157.50k0.36%
Deka Investment GmbHas of 30 Nov 202255.39k0.35%
Lupus alpha Asset Management AGas of 31 Dec 202250.00k0.31%
Ehrke & L�bberstedt AGas of 31 Mar 202344.08k0.28%
TBF Global Asset Management GmbHas of 31 Mar 202343.05k0.27%
Norges Bank Investment Managementas of 31 Dec 202237.90k0.24%
Lloyd Fonds AG (Mutual Fund Manager)as of 31 Mar 202336.00k0.22%
Plutos Verm�gensverwaltung AGas of 28 Apr 202332.00k0.20%
ACATIS Investment Kapitalverwaltungsgesellschaft mbHas of 28 Apr 202331.52k0.20%
More ▼
Data from 30 Sep 2021 - 31 May 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.